Precorneal retention time of ocular lubricants measured with fluorophotometry in healthy dogs.

OBJECTIVE Determine the precorneal retention time of five different ocular lubricants commonly used in dogs. ANIMALS STUDIED Six healthy Beagle dogs (n = 12 eyes). PROCEDURES Five ocular lubricants were studied: Artificial Tears Solution® (1.4% polyvinyl alcohol), I-Drop® Vet Plus (0.25% hyaluronate), Optixcare® Eye Lube Plus (0.25% hyaluronate), Systane® Ultra (0.4% polyethylene glycol 400 and 0.3% propylene glycol), and Artificial Tears Ointment® (mineral oil/white petrolatum). Each lubricant was mixed with 10% sodium fluorescein to achieve 1% fluorescein formulations. Following topical administration of 35 mg in each eye, tear fluid was collected with capillary tubes at selected times (0, 1, 5, 10, 20, 30, 40, 50, 60, 90, 120, 180 min) and fluorescein concentrations were measured with a computerized scanning ocular fluorophotometer. RESULTS Tear fluorescence was significantly greater with Artificial Tears Ointment® compared with other lubricant formulations from 1 to 20 min post-administration. Median (range) precorneal retention times were significantly different among the 5 lubricants, ranging from 40 minutes (20-90 min) for Artificial Tears Ointment®, 35 min (20-90 min) for Systane® Ultra, 30 min (10-60 min) for I-Drop® Vet Plus, 25 min (10-60 min) for Optixcare® Eye Lube Plus, and 10 min (10-20 min) for Artificial Tears Solution®. Precorneal retention time was significantly lower for Artificial Tears Solution® compared with the other 4 formulations. CONCLUSIONS This study established normative data for the retention time of common lubricants on the ocular surface of dogs, which may be used to guide clinicians with their choice of lubricant and frequency of administration.

[1]  Dikla Arad,et al.  Mucoadhesive Polymers Enhance Ocular Drug Delivery: Proof of Concept Study with 0.5% Tropicamide in Dogs. , 2021, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[2]  Ajay Sharma,et al.  Categorization of Marketed Artificial Tear Formulations Based on Their Ingredients: A Rational Approach for Their Use , 2021, Journal of clinical medicine.

[3]  A. Bernkop‐Schnürch,et al.  Strategies to prolong the residence time of drug delivery systems on ocular surface. , 2020, Advances in colloid and interface science.

[4]  J. Mochel,et al.  Tear Film Pharmacokinetics and Systemic Absorption Following Topical Administration of 1% Prednisolone Acetate Ophthalmic Suspension in Dogs , 2020, Frontiers in Veterinary Science.

[5]  P. Campochiaro,et al.  Gelling hypotonic polymer solution for extended topical drug delivery to the eye , 2020, Nature Biomedical Engineering.

[6]  J. Mochel,et al.  Impact of acute conjunctivitis on ocular surface homeostasis in dogs. , 2020, Veterinary ophthalmology.

[7]  J. Mochel,et al.  An eye on the dog as the scientist's best friend for translational research in ophthalmology: Focus on the ocular surface , 2020, Medicinal research reviews.

[8]  G. Fatone,et al.  Schirmer Tear Test Value and Corneal Lesions’ Incidence during General Anesthesia for Non-Ophthalmic Surgery in Non-Brachycephalic Dogs: A Pilot Study Comparing Three Different Lubricant Eye Drop Formulations , 2020, Veterinary sciences.

[9]  R. Dana,et al.  Advances and limitations of drug delivery systems formulated as eye drops. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[10]  J. Mochel,et al.  Kinetics of Fluorescein in Tear Film After Eye Drop Instillation in Beagle Dogs: Does Size Really Matter? , 2019, Front. Vet. Sci..

[11]  J. Mochel,et al.  Fluorophotometric Assessment of Tear Volume and Turnover Rate in Healthy Dogs and Cats , 2019, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[12]  J. Mochel,et al.  Histamine-Induced Conjunctivitis and Breakdown of Blood–Tear Barrier in Dogs: A Model for Ocular Pharmacology and Therapeutics , 2019, Front. Pharmacol..

[13]  David T. Douglass,et al.  Evaluation of an enhanced viscosity artificial tear for moderate to severe dry eye disease: A multicenter, double-masked, randomized 30-day study. , 2019, Contact lens & anterior eye : the journal of the British Contact Lens Association.

[14]  Xiuming Jin,et al.  Evaluation of artificial tears on cornea epithelium healing. , 2018, International journal of ophthalmology.

[15]  G. Malaguarnera,et al.  Measurement of the Retention Time of Different Ophthalmic Formulations with Ultrahigh-Resolution Optical Coherence Tomography , 2016, Current eye research.

[16]  B. Mann,et al.  Topical Cross-Linked HA-Based Hydrogel Accelerates Closure of Corneal Epithelial Defects and Repair of Stromal Ulceration in Companion Animals. , 2017, Investigative ophthalmology & visual science.

[17]  V. K. Raghunathan,et al.  Species variation and spatial differences in mucin expression from corneal epithelial cells. , 2016, Experimental eye research.

[18]  A. Tichy,et al.  Clinical effect of four different ointment bases on healthy cat eyes. , 2016, Veterinary ophthalmology.

[19]  R. Sanchez,et al.  A prospective study of the prevalence of corneal surface disease in dogs receiving prophylactic topical lubrication under general anesthesia. , 2016, Veterinary ophthalmology.

[20]  Sueko M Ng,et al.  Over the counter (OTC) artificial tear drops for dry eye syndrome. , 2016, The Cochrane database of systematic reviews.

[21]  P. L. Dodi,et al.  Immune-mediated keratoconjunctivitis sicca in dogs: current perspectives on management , 2015, Veterinary medicine.

[22]  P. Kador,et al.  Topical nutraceutical Optixcare EH ameliorates experimental ocular oxidative stress in rats. , 2014, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[23]  M. Moshirfar,et al.  Artificial tears potpourri: a literature review , 2014, Clinical ophthalmology.

[24]  P. Aragona,et al.  Towards a dynamic customised therapy for ocular surface dysfunctions , 2013, British Journal of Ophthalmology.

[25]  K. Hosny,et al.  Ketorolac Tromethamine In-situ Ocular Hydro Gel; Preparation, Characterization, and In-vivo Evaluation , 2011 .

[26]  H Zhao,et al.  Ocular Surface Dwell Time of Artificial Tears Measured with Fluorometry in Chinese Dry Eye Patients , 2011 .

[27]  T. Nishida,et al.  Fluorophotometric measurement of the precorneal residence time of topically applied hyaluronic acid , 2007, British Journal of Ophthalmology.

[28]  B. Grahn,et al.  Lacrimostimulants and lacrimomimetics. , 2004, The Veterinary clinics of North America. Small animal practice.

[29]  Jianhua Wang,et al.  Precorneal and pre- and postlens tear film thickness measured indirectly with optical coherence tomography. , 2003, Investigative ophthalmology & visual science.

[30]  N. J. Haeringen Aging and the lacrimal system , 1997 .

[31]  R S Baker,et al.  Age-related changes in human blinks. Passive and active changes in eyelid kinematics. , 1997, Investigative ophthalmology & visual science.

[32]  G. Snibson,et al.  Ocular Surface Residence Times of Artificial Tear Solutions , 1992, Cornea.

[33]  A. Ludwig,et al.  Formulation of Carbopol 940 ophthalmic vehicles, and in vitro evaluation of the influence of simulated lacrimal fluid on their physico-chemical properties. , 1991, Die Pharmazie.

[34]  J. Prydal,et al.  Precorneal residence times of sodium hyaluronate solutions studied by quantitative gamma scintigraphy , 1990, Eye.

[35]  C. Hanna,et al.  Effects of drug vehicles on ocular contact time. , 1975, Archives of ophthalmology.